The Career Development Program supports young Investigators pursuing careers in translational lymphoma research and also supports established investigators who wish to refocus their work on lymphoma. This program supports two individuals per year and provides 1-2 years of support for each awardee. The program is co-ordinated by the Administrative Core with oversight from the Executive Committee and Advisory Board. The program has well-defined processes for candidate recruitment, and will continue its successful efforts to recruit women and minorities. Both MD and PhD trainees selected by this program will be able to take advantage of courses available through the Clinical Scientist Training Program at BCM and will have a strong group of mentors with broad translational expertiseOijr mentoring strategies enhance the training program by providing trainees with multiple mentors who possess complementary skills, and planning Individualized training schemes. Additionally, trainees have access to the SPORE cores (clinical research, biostatistics, cell processing and vector production) which provide them with unique expertise in cell and gene therapy and clinical research. In the last 4 years, 6 trainees have been supported by this program and all have subsequently obtained independent peer-reviewed funding;three are now Incorporated Into SPORE projects.

Public Health Relevance

The goal of this program is to provide training in translational research In lymphoma, thereby Increasing the number of well qualified and trained investigators jn basic science, population science and clinical research who will contribute to improving lymphoma treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA126752-07
Application #
8547762
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
7
Fiscal Year
2013
Total Cost
$152,165
Indirect Cost
$66,821
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Velasquez, Mireya Paulina; Szoor, Arpad; Vaidya, Abishek et al. (2017) CD28 and 41BB Costimulation Enhances the Effector Function of CD19-Specific Engager T Cells. Cancer Immunol Res 5:860-870
Gomes-Silva, Diogo; Srinivasan, Madhuwanti; Sharma, Sandhya et al. (2017) CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 130:285-296
Rouce, Rayne H; Sharma, Sandhya; Huynh, Mai et al. (2017) Recent advances in T-cell immunotherapy for haematological malignancies. Br J Haematol 176:688-704
Huang, Yung-Hsin; Su, Jianzhong; Lei, Yong et al. (2017) DNA epigenome editing using CRISPR-Cas SunTag-directed DNMT3A. Genome Biol 18:176
Schmueck-Henneresse, Michael; Omer, Bilal; Shum, Thomas et al. (2017) Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells. J Immunol 199:348-362
Lei, Yong; Zhang, Xiaotian; Su, Jianzhong et al. (2017) Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein. Nat Commun 8:16026
Lulla, Premal; Ramos, Carlos A (2017) Expanding Accessibility to CD19-CAR T Cells: Commercializing a ""Boutique"" Therapy. Mol Ther 25:8-9
Peckham-Gregory, Erin C; Chakraborty, Rikhia; Scheurer, Michael E et al. (2017) A genome-wide association study of LCH identifies a variant in SMAD6 associated with susceptibility. Blood 130:2229-2232
Gomes-Silva, Diogo; Mukherjee, Malini; Srinivasan, Madhuwanti et al. (2017) Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep 21:17-26
Liu, Hao; Shen, Yu; Ning, Jing et al. (2017) Sample size calculations for prevalent cohort designs. Stat Methods Med Res 26:280-291

Showing the most recent 10 out of 244 publications